The National Pancreatic Cyst Registry | Logistics
712
page-template-default,page,page-id-712,ajax_leftright,page_not_loaded,boxed,no_delay
 
 

Study Inclusion Criteria

 

  • Patients must have been previously evaluated with integrated molecular pathology.

  • Patients could not have been treated for pancreatic cancer prior to integrated molecular pathology.

  • Benign outcomes were defined as no evidence of malignancy after two or more years of clinical follow up.

  • Malignant outcomes were determined by positive cytology, evidence of cancer from surgical pathology, or clinical cancer treatment.

Length of
follow up

Source of outcome

Surgical pathology

Positive cytology

Clinical cancer management

EUS/imaging surveillance

<6 months

168

16

3

0

6 months–1y

15

3

2

1

1-2 y

13

1

0

5

2-3 y

10

0

0

134

3-4 y

1

0

0

74

4-5 y

1

0

0

37

>5 y

1

0

0

7

Total

209

20

5

258